Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome.
Department of Emergencies and Critical Care Department of Immunology, Oslo University Hospital K.G. Jebsen IRC, University of Oslo.
Andreas
A
Barratt-Due
Department of Haematology, Oslo University Hospital.
Yngvar
Y
Fløisand
Department of Immunology, Oslo University Hospital K.G. Jebsen IRC, University of Oslo.
Hilde L
HL
Orrem
Department of Haematology, Oslo University Hospital.
Ann K
AK
Kvam
Department of Haematology, Oslo University Hospital Institute of Clinical Medicine, University of Oslo, Oslo.
Pål A
PA
Holme
Research Laboratory Nordland Hospital, Bodø K.G. Jebsen TREC, University of Tromsø, Tromsø and.
Grethe
G
Bergseth
Department of Haematology, Oslo University Hospital Institute of Clinical Medicine, University of Oslo, Oslo.
Geir E
GE
Tjønnfjord
Department of Immunology, Oslo University Hospital K.G. Jebsen IRC, University of Oslo Research Laboratory Nordland Hospital, Bodø K.G. Jebsen TREC, University of Tromsø, Tromsø and Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway andreas.barrattdue@gmail.com.
Tom E
TE
Mollnes
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000276:immunology*; D002388:Catastrophic Illness / Q000628:therapy; D003167:Complement Activation / Q000276:immunology*; D051056:Complement Inactivating Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans
D061067:Antibodies, Monoclonal, Humanized; D051056:Complement Inactivating Agents; C481642:eculizumab